Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB)

被引：3

作者：

Lipsitz, E. G.

Nguyen, V.

Zhao, H.

Ecsedy, J.

Maris, J. M.

Adamson, P. C.

Mosse, Y. P.

机构：

[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[2] Childrens Hosp, Philadelphia, PA 19104 USA

[3] Millennium Pharmaceut Inc, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.10593

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10593

引用

页数：1

共 50 条

[1] Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth
Zhang, Yuebo
Ma, Yong
Wang, Ying
Mukhopadhyay, Debabrata
Bi, Yan
Ji, Baoan
PANCREATOLOGY, 2022, 22 (05) : 619 - 625
[2] Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
Tayyar, Yaman
Shiels, Ryan
Bulmer, Andrew C.
Lam, Alfred K.
Clarke, Daniel
Idris, Adi
McMillan, Nigel A.
PLOS ONE, 2019, 14 (11):
[3] Initial Testing of the Aurora Kinase A Inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
Maris, John M.
Morton, Christopher L.
Gorlick, Richard
Kolb, E. Anders
Lock, Richard
Carol, Hernan
Keir, Stephen T.
Reynolds, C. Patrick
Kang, Min H.
Wu, Jianrong
Smith, Malcolm A.
Houghton, Peter J.
PEDIATRIC BLOOD & CANCER, 2010, 55 (01) : 26 - 34
[4] Aurora Kinase a Inhibitor MLN8237 Inhibits the Growth of Pancreatic Cancer Both In Vitro and In Vivo
Zhang, Y.
Ma, Y.
Wang, Y.
Haddock, A.
Mukhopadhyay, D.
Bi, Y.
Ji, B.
PANCREAS, 2017, 46 (10) : 1447 - 1447
[5] Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies
Padmanabhan, Swaminathan
Shea, Thomas C.
Vose, Julie M.
Reeder, Craig B.
Berdeja, Jesus G.
McDonagh, Kevin T.
Goy, Andre
Kelly, Kevin R.
Zhou, Xiaofei
Liu, Hua
Fingert, Howard
Fowler, Nathan
BLOOD, 2010, 116 (21) : 1154 - 1154
[6] MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials
Sells, Todd
Ecsedy, Jeffrey
Stroud, Stephen
Janowick, David
Hoar, Kara
Leroy, Patrick
Wysong, Deborah
Zhang, Mengkun
Huck, Jessica
Silverman, Lee
Chen, Wei
Bembenek, Michael
Claiborne, Christopher
Manfredi, Mark
CANCER RESEARCH, 2008, 68 (09)
[7] Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237
Smith, M. A.
Houghton, P. J.
Morton, C. L.
Maris, J. M.
Courtright, J.
Carol, H.
Lock, R. B.
Yang, Y.
Manfredi, M. G.
EJC SUPPLEMENTS, 2008, 6 (12): : 92 - 93
[8] Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
Carol, Hernan
Boehm, Ingrid
Reynolds, C. Patrick
Kang, Min H.
Maris, John M.
Morton, Christopher L.
Gorlick, Richard
Kolb, E. Anders
Keir, Stephen T.
Wu, Jianrong
Wozniak, Amy E.
Yang, Yu
Manfredi, Mark
Ecsedy, Jeffrey
Wang, Jianmin
Neale, Geoffrey
Houghton, Peter J.
Smith, Malcolm A.
Lock, Richard B.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1291 - 1304
[9] MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results
Alvarez, R. H.
DeMichele, A.
Mailliez, A.
Benaim, E.
Fingert, H.
Schusterbauer, C.
Zhang, B.
Melichar, B.
CANCER RESEARCH, 2012, 72
[10] A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.
Gorgun, Gullu
Calabrese, Elisabetta
Hideshima, Teru
Ecsedy, Jeffrey
Bianchi, Giada
Mani, Mala
Bandi, Madhavi
Ikeda, Hiroshi
Perrone, Giulia
Hu, Yiguo
Tai, Yu-Tzu
Zheng, Mei
Cristea, Diana
Santo, Loredana
Carrasco, Daniel R.
Munshi, Nikhil
Richardson, Paul
Anderson, Kenneth C.
BLOOD, 2009, 114 (22) : 1474 - 1474

← 1 2 3 4 5 →